Arthritis Innovation Corporation

What Arthritis Innovation Corporation does

Arthritis Innovation Corporation (AIC) is a privately held, clinical-stage pharmaceutical company headquartered in Toronto, Canada with a secondary office in Denver, Colorado. Its sole development asset is F14, a First-in-Class intra-articular formulation of the FDA-approved COX-2 inhibitor celecoxib, designed as a single intraoperative dose administered at the conclusion of total knee replacement (TKR) surgery to deliver sustained, localized anti-inflammatory therapy over the following weeks. F14 is built on Medincell's BEPO biodegradable PLA-PEG injectable polymer platform, which self-assembles into a semi-solid depot at the injection site and slowly releases encapsulated drug over days to weeks, and is being developed under the FDA 505(b)(2) pathway leveraging Celebrex as the reference drug. The asset has progressed through Phase 2 and into a first Phase 3 registration trial, with a second Phase 3 planned for 2026 and an NDA submission targeted for 2028.

AIC serves two primary end-customers in the long run: TKR patients who experience post-operative pain, inflammation, and delayed functional recovery, and the orthopedic surgeons and hospitals that manage their post-surgical care and currently rely on opioids and systemic NSAIDs with known side-effect profiles. The stated business model is pre-commercial: AIC is actively soliciting strategic partners, licensing deals, or a standalone NDA-and-commercialization path for F14, with stated potential revenue streams of one-time license economics and development/commercial milestones plus royalties. The company has a 1-10 person operating footprint, a small disclosed management team led by CEO Wayne Marshall MD PhD, and only one equity financing on record (a 2017 round of approximately $324,350), with no product revenue disclosed to date.

Name

Arthritis Innovation Corporation

Legal name

Arthritis Innovation Corporation

Website

https://aic.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Arthritis Innovation Corporation is a privately held, clinical-stage pharmaceutical company developing F14, a First-in-Class intra-articular celecoxib formulation using Medincell's BEPO sustained-release polymer platform, targeted at reducing post-operative pain and inflammation following total knee replacement surgery.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals — Intra-articular Drug Delivery

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Hip & Knee Reconstruction (Arthroplasty) (HLAKALAH)

Keywords

• Intra-articular drug delivery
• Sustained-release injectables
• Post-surgical pain management
• Biodegradable polymer therapeutics
• Orthopedic pharmaceutical development

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Once approved, AIC plans to commercialize F14 for post-TKR pain and inflammation. The company is exploring multiple exit pathways including standalone NDA and commercialization or strategic partnership/licensing to a large orthopedic or pharma company.
2. Licensing and Partnership Revenue: AIC is seeking strategic partnerships with large orthopedic or pharma companies. Potential licensing deals could include upfront payments, development milestones, and royalties on sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Arthritis Innovation Corporation is developing F14, a First-in-Class intra-articular celecoxib formulation that combines Medincell's BEPO® biodegradable sustained-release polymer platform with the FDA-approved COX-2 inhibitor celecoxib. F14 is administered as a single intraoperative injection at the conclusion of total knee replacement surgery to deliver sustained, localized anti-inflammatory therapy over weeks, reducing post-operative pain and accelerating functional recovery. F14 is currently in Phase 3 clinical development.

Product overview

Arthritis Innovation Corporation is a clinical-stage pharmaceutical company with a single lead product: F14. F14 is a First-in-Class intra-articular formulation of celecoxib leveraging Medincell's clinically validated BEPO long-acting injectable polymer platform. The product is administered as a single intraoperative injection directly into the knee joint at the conclusion of total knee replacement surgery. The company's portfolio consists solely of F14 at present, with no additional products, modules, or platform extensions mentioned.

Differentiator

Problem solved

Functional benefit

Brands

• F14: A First-in-Class intra-articular celecoxib formulation designed to reduce post-operative pain and inflammation resulting in accelerated functional recovery after total knee replacement. Currently in Phase 3.

Products and services

• F14 Intra-articular Celecoxib Formulation F14 is a First-in-Class intra-articular celecoxib formulation that combines Medincell's BEPO® biodegradable sustained-release polymer platform with the FDA-approved COX-2 inhibitor celecoxib. It is designed as a single intraoperative injection administered at the conclusion of total knee replacement surgery to deliver sustained, localized anti-inflammatory therapy that reduces post-operative pain and accelerates functional recovery. F14 is targeted at orthopedic surgeons and hospitals performing TKR procedures and is currently in Phase 3 clinical development.

Quantifiable outcome

• Measurable plasma concentrations of celecoxib for up to 6 weeks following single intra-articular administration
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered major, core and minor.

• AbbViemajorStrategic or Co-development Partner · 1 April 2024In April 2024, AbbVie entered into a strategic co-development and licensing agreement with Medincell covering up to six long-acting injectable programs across multiple therapeutic areas. Medincell received $35 million upfront payment and is eligible for up to $1.9 billion in development and commercial milestones plus royalties. This partnership validates the BEPO® platform technology.
• MedincellcoreTechnology or IntegrationAIC licenses BEPO® technology from Medincell for the F14 formulation. BEPO® is a biodegradable, injectable sustained-release technology based on PLA-PEG copolymer mixture. F14 uses this technology combined with celecoxib to create a sustained-release intra-articular formulation for post-TKR pain and inflammation.
• Teva PharmaceuticalsmajorTechnology or IntegrationTeva licensed Medincell's BEPO® long-acting injectable technology platform (commercialized as SteadyTeq™) for CNS programs including UZEDY® and long-acting olanzapine. While not directly with AIC, Teva's partnership with Medincell validates the BEPO® technology platform that AIC uses for F14.
• Bill & Melinda Gates FoundationminorStrategic or Co-development PartnerThe Bill & Melinda Gates Foundation has licensed BEPO® technology from Medincell for global health applications, demonstrating the breadth of BEPO®'s applicability.
• CorbionminorStrategic or Co-development PartnerCorbion has partnered with Medincell as a biomaterials licensee, further demonstrating BEPO® technology's versatility.

Scale indicators9 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Zimmer Biomet: Zimmer Biomet is a major orthopedic implant company that performs and supports a large share of TKR procedures globally; it is a potential strategic acquirer/partner and shapes the surgical workflow, implants, and adjuvant therapy ecosystem in which F14 would be administered.
• Teva Pharmaceutical Industries: Teva commercializes UZEDY (a BEPO®-based long-acting injectable) via its partnership with Medincell; Teva validates the BEPO® platform AIC uses for F14 and is a potential strategic partner or comparable commercial-stage reference for the same underlying technology.
• Stryker: Stryker is a leading orthopedic medical device company with significant TKR franchise (Mako robotic-assisted TKR); it is a potential strategic partner and a key stakeholder in post-TKR pain management protocols where F14 would be integrated.
• AbbVie: AbbVie entered a 2024 co-development deal with Medincell covering up to six BEPO® long-acting injectable programs ($35M upfront, up to $1.9B in milestones); it is a potential strategic partner for AIC and a key validator of the BEPO® platform's commercial value across therapeutic areas.
• Pfizer (Celebrex): Pfizer manufactures and markets Celebrex (celecoxib), the reference drug for AIC's 505(b)(2) regulatory strategy; while a broad incumbent in oral NSAIDs rather than a direct intra-articular competitor, Pfizer's commercialization of celecoxib anchors F14's safety/efficacy reference and physician familiarity.

Direct peers

• Heron Therapeutics: Heron developed and commercialized ZYNRELEF, a long-acting dual-acting local anesthetic for post-surgical pain; it is a direct competitor to F14 in the post-operative, non-opioid, sustained-release analgesia space targeted at surgical-site recovery.
• Flexion Therapeutics: Flexion commercialized ZILRETTA, an intra-articular extended-release corticosteroid for knee osteoarthritis; it pioneered the intra-articular sustained-release concept for the knee that F14 also leverages for post-TKR anti-inflammatory therapy.
• Pacira BioSciences: Pacira markets EXPAREL, a long-acting local anesthetic widely used for post-surgical pain management including in TKR; both companies pursue non-opioid, long-acting injectable therapies targeting the post-TKR analgesia market that F14 is also addressing.
• Anika Therapeutics: Anika develops and commercializes intra-articular therapies (e.g., hyaluronic acid-based viscosupplements like Monovisc/Orthovisc) for knee osteoarthritis; it operates in the same intra-articular knee treatment paradigm F14 targets.

Others

• Medincell: Medincell is the licensor of the BEPO® sustained-release polymer technology that underpins F14; while not a commercial competitor, Medincell is the core enabling technology platform for AIC and its broader pipeline (including partnerships with Teva and AbbVie) directly affects F14's trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/in/wayne-marshall-68a3b1a4

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arthritis Innovation Corporation